CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$2.19
+0.05 (+2.34%)
Open$2.24
Previous Close$2.14
Day High$2.27
Day Low$2.12
52W High$8.21
52W Low$2.11
Volume—
Avg Volume5.03M
Market Cap484.83M
P/E Ratio—
EPS$-0.44
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,778.5% upside
Current
$2.19
$2.19
Target
$63.04
$63.04
$39.26
$63.04 avg
$88.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 122.29M | 108.49M | 145.29M |
| Net Income | -27,871,952 | -22,254,042 | 18.60M |
| Profit Margin | -22.8% | -21.7% | 12.8% |
| EBITDA | -33,915,672 | -28,584,003 | 25.56M |
| Free Cash Flow | — | — | 18.27M |
| Rev Growth | +12.7% | +12.7% | +5.8% |
| Debt/Equity | — | — | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |